The clinical spectrum of thrombocytosis and thrombocythemia.

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Platelet production is the result of a highly ordered maturation of a developmental hierarchy of megakaryocytic progenitor cells regulated by a variety of cytokines. GM-CSF, II-3 and II-6 have a stimulatory effect and several cytokines (TGF-beta, platelet released glycoprotein, platelet factor 4 and interferons) have inhibitory effects down regulating platelet production perhaps as part of an autocrine control loop. Excess platelet production can be clinically characterized as pseudothrombocytosis, thrombocytosis or thrombocythemia; the clinical features and criteria for each are defined. The term thrombocytosis infers its reactive nature and, in the absence of arterial disease or prolonged immobility, it poses little risk regardless of platelet numbers. By contrast, in thrombocythemia, whether primary or associated with other myeloproliferative lesions, significant thrombohemorrhagic events occur. The natural history, rationale, and approach to platelet reduction and control of clinical sequela are reviewed. Clinical therapeutic options include a new agent, Anagrelide.

Original languageEnglish (US)
Pages (from-to)69-80
Number of pages12
JournalAmerican Journal of the Medical Sciences
Volume301
Issue number1
StatePublished - Jan 1991

Fingerprint

Thrombocytosis
Blood Platelets
Cytokines
Platelet Membrane Glycoproteins
Platelet Factor 4
Essential Thrombocythemia
Granulocyte-Macrophage Colony-Stimulating Factor
Natural History
Platelet Count
Transforming Growth Factor beta
Interferons
Stem Cells
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The clinical spectrum of thrombocytosis and thrombocythemia. / Frenkel, E. P.

In: American Journal of the Medical Sciences, Vol. 301, No. 1, 01.1991, p. 69-80.

Research output: Contribution to journalArticle

@article{2db74d57cb51421989032b7abf44268f,
title = "The clinical spectrum of thrombocytosis and thrombocythemia.",
abstract = "Platelet production is the result of a highly ordered maturation of a developmental hierarchy of megakaryocytic progenitor cells regulated by a variety of cytokines. GM-CSF, II-3 and II-6 have a stimulatory effect and several cytokines (TGF-beta, platelet released glycoprotein, platelet factor 4 and interferons) have inhibitory effects down regulating platelet production perhaps as part of an autocrine control loop. Excess platelet production can be clinically characterized as pseudothrombocytosis, thrombocytosis or thrombocythemia; the clinical features and criteria for each are defined. The term thrombocytosis infers its reactive nature and, in the absence of arterial disease or prolonged immobility, it poses little risk regardless of platelet numbers. By contrast, in thrombocythemia, whether primary or associated with other myeloproliferative lesions, significant thrombohemorrhagic events occur. The natural history, rationale, and approach to platelet reduction and control of clinical sequela are reviewed. Clinical therapeutic options include a new agent, Anagrelide.",
author = "Frenkel, {E. P.}",
year = "1991",
month = "1",
language = "English (US)",
volume = "301",
pages = "69--80",
journal = "The American journal of the medical sciences",
issn = "0002-9629",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - The clinical spectrum of thrombocytosis and thrombocythemia.

AU - Frenkel, E. P.

PY - 1991/1

Y1 - 1991/1

N2 - Platelet production is the result of a highly ordered maturation of a developmental hierarchy of megakaryocytic progenitor cells regulated by a variety of cytokines. GM-CSF, II-3 and II-6 have a stimulatory effect and several cytokines (TGF-beta, platelet released glycoprotein, platelet factor 4 and interferons) have inhibitory effects down regulating platelet production perhaps as part of an autocrine control loop. Excess platelet production can be clinically characterized as pseudothrombocytosis, thrombocytosis or thrombocythemia; the clinical features and criteria for each are defined. The term thrombocytosis infers its reactive nature and, in the absence of arterial disease or prolonged immobility, it poses little risk regardless of platelet numbers. By contrast, in thrombocythemia, whether primary or associated with other myeloproliferative lesions, significant thrombohemorrhagic events occur. The natural history, rationale, and approach to platelet reduction and control of clinical sequela are reviewed. Clinical therapeutic options include a new agent, Anagrelide.

AB - Platelet production is the result of a highly ordered maturation of a developmental hierarchy of megakaryocytic progenitor cells regulated by a variety of cytokines. GM-CSF, II-3 and II-6 have a stimulatory effect and several cytokines (TGF-beta, platelet released glycoprotein, platelet factor 4 and interferons) have inhibitory effects down regulating platelet production perhaps as part of an autocrine control loop. Excess platelet production can be clinically characterized as pseudothrombocytosis, thrombocytosis or thrombocythemia; the clinical features and criteria for each are defined. The term thrombocytosis infers its reactive nature and, in the absence of arterial disease or prolonged immobility, it poses little risk regardless of platelet numbers. By contrast, in thrombocythemia, whether primary or associated with other myeloproliferative lesions, significant thrombohemorrhagic events occur. The natural history, rationale, and approach to platelet reduction and control of clinical sequela are reviewed. Clinical therapeutic options include a new agent, Anagrelide.

UR - http://www.scopus.com/inward/record.url?scp=0025983051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025983051&partnerID=8YFLogxK

M3 - Article

VL - 301

SP - 69

EP - 80

JO - The American journal of the medical sciences

JF - The American journal of the medical sciences

SN - 0002-9629

IS - 1

ER -